* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Nursing Process Focus: Patients Receiving Lorazepam (Ativan
Survey
Document related concepts
Transcript
Nursing Process Focus: Patients Receiving Lorazepam (Ativan) Assessment Potential Nursing Diagnoses Prior to administration: • Injury, Risk for, related to sedative • Obtain complete medical history: effect of drug pulmonary, cardiac, renal, biliary, and • Memory, Impaired related to side effect mental or sleep disorders, including EKG of drug and laboratory studies: CBC, BUN, • Knowledge, Deficient, related to newly creatinine, electrolytes, liver functions prescribed drug tests. • Ineffective individual coping • Obtain patient’s drug history to determine • Sleep pattern Disturbed, related to side possible drug interactions and allergies effect of drug Planning: Patient Goals and Expected Outcomes Patient will: • Experience an increase in psychological comfort • Report absence of physical and behavioral manifestations of anxiety • Demonstrate understanding of the drug's action by accurately describing drug side effects and precautions. • Remain free of injury • Maintain intact memory Implementation Interventions and (Rationales) Patient Education / Discharge Planning • Ensure patient safety. Raise bedrails; Instruct patient: place • to request assistance when getting out of • call bell within patient's reach. bed and ambulating until effect of drug is Lorazepam causes drowsiness and known dizziness. • to avoid activities that require mental alertness and good physical coordination until effect of drug is known • Monitor patient for signs of digoxin Instruct patient: toxicity. (Lorazepam may contribute to • also taking digoxin of the symptoms of digoxin toxicity by increasing the digoxin intoxication. serum digoxin level. Symptoms include • to immediately report signs and symptoms visual changes such as yellow auras, of digoxin toxicity. blurring or diplopia; nausea, vomiting and diarrhea, paraesthesias, dizziness, confusion, vertigo, profound weakness, syncope, etc.) • Monitor vital signs especially pulse, Instruct patient respirations, and blood pressure. • Regarding methods to monitor vital signs Observe respiratory patterns, especially at home, especially respirations, as needed, during sleep, for evidence of apnea or and that snoring is NOT normal; it is a shallow breathing. (Lorazepam can sound created by obstruction in the upper reduce the respiratory drive in respiratory tract. susceptible patients.) • • Monitor the patient's intake of ordinary stimulants, including caffeine (in beverages such as coffee, tea, cola and other soft drinks and over-the-counter analgesicssuch as Excedrin®), and nicotine (smoking, tobacco-chewing and nicotine patches). Monitor vital signs and neurological status, especially level of consciousness (LOC). • Monitor affect and emotional status. Monitor for depression, especially with suicidal tendencies: use with caution. (Drug may increase risk.) • Monitor liver function. (Lorazepam is metabolized in the liver, creating the risk for liver toxicity.) Signs and symptoms include nausea, vomiting, diarrhea, rash, jaundice, abdominal pain, tenderness or distention, or change in color of stool. Use with caution in patients who have or are suspected as having a primary sleep disorder. (The CNS depressant effect of lorazepam can further affect the altered respiratory drive responsible for central sleep apnea and can increase muscle relaxation in the upper airway, enhancing mechanical occlusion of the upper airway, and worsening obstructive sleep apnea. CNS depressants exacerbate hypersomnolence (excessive daytime sleepiness) associated with narcolepsy) Avoid abrupt discontinuation of therapy. (Withdrawal symptoms are possible with abrupt discontinuation after long term use.) • • • Instruct the patient that caffeine and nicotine (and other stimulants) can reduce the drug's effectiveness. Instruct patient to report significant changes in neurological status, such as extreme lethargy, slurred speech, disorientation or ataxia. Instruct patient: • To report significant mood changes, especially depression. • Obtain a verbal "no-self harm" contract from the patient. • To keep all follow-up appoints as directed by health-care provider. Instruct the patient: • To report signs and symptoms of hepatic toxicity. • To adhere to a regular schedule of laboratory testing for liver function as ordered by the health care provider. • • Advise patient that, if snoring occurs, consult the health care provider before taking this medication. Instruct patient • To take drug exactly as prescribed. • To keep follow up appointments to monitor response to medication. • That abrupt discontinuation may result in rebound anxiety and sleeplessness, possibly of enhanced intensity. Evaluation of Outcome Criteria Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see “Planning”) Nursing Process Focus: Patients Receiving Zolpidem (Ambien) Assessment • Potential Nursing DiagnoseRisk Prior to administration: for, related to sedative effect of • Obtain complete medical history, drug including, allergies, data on sleep • Sleep pattern, Disturbed, related to habits, mental status and any family effects of drug history of sleep disorders, and • Memory, Impaired, related to side laboratory findings such as CBC, BUN effect of drug creatinine, and liver enzymes. • Knowledge, Deficient, related to • Obtain patient’s drug history to new drug regimen determine possible drug interactions and allergies Planning: Patient Goals and Expected Outcomes Patient will: • Experience comfortable, timely onset of night-time sleep and restoration of normal sleep/wake pattern. • Demonstrate understanding of sleep hygiene and factors that facilitate sleep. • Demonstrate understanding of the drug's action by accurately describing drug side effects and precautions. • Remain free of injury during course of drug therapy. Implementation Interventions and (Rationales) Patient Education / Discharge Planning • Monitor patients having a primary Advise patient sleep disorder, especially central sleep • To report symptoms of night time apnea. (The CNS depressant effect can shortness of breath, snoring, or further reduce the altered respiratory headache upon awakening to the health drive responsible for apnea.) care provider before taking this medication. • That snoring is NOT normal, and is the sign of obstruction in the upper respiratory tract. • Monitor vital signs especially • Instruct patient or caregiver to monitor respiration, pulse and blood pressure. breathing patterns, and to observe for (The drug's CNS effects can slow or snoring or apnea. diminish breathing.) • Provide for patient safety by toileting Instruct the patient patient prior to medicating, putting side • To request assistance when getting out rails up, placing call bell nearby, etc. of bed (Grogginess can cause the patient to • To remove items from the home that become disoriented, and to forget or pose a tripping hazard. disregard object placement.) • Monitor mental status and level of • Instruct the patient or caregiver to consciousness. (The drug's affect on report significant changes in mental the hippocampus and cerebral cortex status, such as extreme lethargy or may cause confusion or amnesia.) disorientation, especially occuring in the daytime. • Monitor mental health status and evaluate risk potential for suicide. • Monitor the environment for signs of hoarding medication. Obtain a no-self harm verbal contract from patients identified as being at risk of suicide. • Document patient’s sleep patterns and response to medication • Monitor gastrointestinal elimination. Observe for nausea, vomiting, and dyspepsia. CNS depressants may reduce gastrointestinal motility. (Gastrointestinal distress may also signal hepatotoxicity. ) Monitor laboratory tests such as CBC, BUN, creatinine, urinalysis and liver enzymes to determine kidney and liver function. (Zolpidem is metabolized in the liver and excreted by the kidneys; impaired organ function can increase serum drug levels.) • Advise patient to report signs of depression to the health care provider immediately. Instruct patient or caregivers: • To take medication as prescribed. • To assure medications are swallowed. • Instruct patients at risk for mental depression to demonstrate swallowing of the medication. Advise patient: • Of short term use of medications and encourage non-pharmacologic strategies to improve sleep • That long-term insomnia may signal another underlying medical disorder and should be investigated by the health care provider. • Inform patient that food decreases absorption and will delay onset of effects. Advise patient • To inform the health care provider of any history of liver or kidney problems. • To report nausea, vomiting, diarrhea, rash, jaundice, abdominal pain, tenderness, distention, or change in color of stool. • To adhere to laboratory testing regimen for serum blood level tests of liver enzymes as directed. Instruct the patient to keep all follow-up appoints as directed by the health-care provider. Evaluation of Outcome Criteria Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see “Planning”) •